Recent CERO News
- CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split • GlobeNewswire Inc. • 01/06/2025 01:00:00 PM
- CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO • GlobeNewswire Inc. • 12/06/2024 02:00:00 PM
- CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia • GlobeNewswire Inc. • 11/15/2024 01:45:00 PM
- CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity • GlobeNewswire Inc. • 11/11/2024 01:15:00 PM
- CERo Therapeutics, Inc. Provides Corporate Update • GlobeNewswire Inc. • 10/21/2024 01:00:00 PM
- CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer • GlobeNewswire Inc. • 10/02/2024 01:15:00 PM
- CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236 • GlobeNewswire Inc. • 09/25/2024 01:17:00 PM
- CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024 • GlobeNewswire Inc. • 07/08/2024 12:00:00 PM
- CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236 • GlobeNewswire Inc. • 06/13/2024 12:15:00 PM
- CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236 • GlobeNewswire Inc. • 06/06/2024 12:00:00 PM
- CERo Therapeutics, Inc. Provides Corporate Update for Shareholders • GlobeNewswire Inc. • 05/15/2024 12:00:00 PM
- CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes • GlobeNewswire Inc. • 04/30/2024 01:00:00 PM
- CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients • Business Wire • 03/07/2024 12:00:00 PM
UAV Corp Skyborne Technology Secures $105M in Sales Contract LOIs for Revolutionary DART Series Airships • UMAV • Jan 13, 2025 11:00 AM
SANUWAVE Health Announces Preliminary Revenue Results for the Fourth Quarter 2024 (Ended December 31, 2024) • SNWV • Jan 13, 2025 8:10 AM
SANUWAVE Health Appoints Industry Veteran Timothy Wern as Executive Vice President of Sales • SNWV • Jan 13, 2025 8:08 AM
North Bay Resources Announces Operation of New Gravity Circuit at Bishop Gold Mill, California • NBRI • Jan 10, 2025 8:29 AM
Cannabix Technologies Announces Key Hardware Advancements to Marijuana Breathalyzer Technology • BLO • Jan 9, 2025 8:49 AM
UAV Corp. (UMAV) Further Reduces Authorized Shares to 500 Million • UMAV • Jan 8, 2025 2:27 PM